Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 Trials

Retinal Diseases

Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial

Lancet Neurol

Préterre C, Gaultier A, Obadia M, Vignal C, Mourand I, Plat J, Sablot D, Gaudron M, Rodier G, Godeneche G, Urbanczyk C, Marc G, Massardier E, Adam S, Boulanger M, Marcel S, Mechtouff L, Ronzière T, Calvière L, Godard-Ducceschi S, Barbin L, Lebranchu P, Guillon B, THEIA collaborators

doi: 10.1016/S1474-4422(25)00308-4

Macular Diseases

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Ophthalmology

Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators

doi: 10.1016/j.ophtha.2025.10.028

Macular Diseases

PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in nAMD in Subgroups Defined by Baseline Characteristics

Ophthalmol Retina

Gale RP, Loewenstein A, Zhang X, Leal S, Machewitz T, Sivaprasad S, Wong DT, Zeitz O, Korobelnik JF, PULSAR study investigators

doi: 10.1016/j.oret.2026.02.020

Retinal Diseases

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

Br J Ophthalmol

Nguyen CT, Lassen RKB, Mæng MO, Lee C, Subhi Y, Vorum H, Wykoff CC, Ørskov M, Cehofski LJ

doi: 10.1136/bjo-2025-329273

Macular Diseases

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

Br J Ophthalmol

Chalkiadaki E, Sim YS, Williams O, Elder L, Addison PK, Hamilton RD, Nicholson L, Sivaprasad S, Heng LZ

doi: 10.1136/bjo-2025-328893

Macular Diseases

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Ophthalmol Sci

Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG

doi: 10.1016/j.xops.2026.101087

Further Publications

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials

Ophthalmology

Briceño CA, Idowu OO, Khong JJ, Kuenzel T, Tran AQ, Brittain C, Azumi A, Brockwell L, Ghadiri N, Coronel M, Ruf T, Li D, Salvi M, Garrido-Hermosilla AM, Barteselli G, Ortiz-Perez S, of the SatraGO-1 and SatraGO-2 investigators

doi: 10.1016/j.ophtha.2026.08.039

Macular DiseasesRetinal Diseases

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Ophthalmology

Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG, GATHER2 trial investigators

doi: 10.1016/j.ophtha.2025.12.011

Retinal Diseases

Systemic Thromboembolic Outcomes in Young Patients Following Retinal Vein Occlusions

Retina

Zhang C, Ayoubi M, Lin JB, AbouKasm G, Sonik NR, Sosa-Lockwood J, Berrocal A

doi: 10.1097/IAE.0000000000004700

Related content

Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in nAMD in Subgroups Defined by Baseline Characteristics

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Systemic Thromboembolic Outcomes in Young Patients Following Retinal Vein Occlusions